Citations

Clear

3314 citation(s) found for "Do, Alexander".

Microencapsulated Immunoassays for Detection of Cytokines in Human Blood
Rahimian, Ali , Siltanen, Christian , Feyzizarnagh, Hamid , Escalante, Patricio , Revzin, Alexander

Mayo Clinic

ACS Sensors | February 18, 2019 | Volume: 4 | Issue: 3 | Pages: 578-585

10.1021/acssensors.8b01033 | PMID 30776214 Get It

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
Wallentin, Lars , Andersson, Ulrika , Alexander, John H. , Caterina, Raffaele De , Granger, Christopher B. , Halvorsen, Sigrun , Hanna, Michael , Huber, Kurt , Siegbahn, Agneta , Hanna, Michael G. , Huber, Kurt , Granger, Christopher B , Christersson, Christina , Alings, Marco , Gersh, Bernard J. , Hylek, Elaine M. , Lópes, Renato D. , Oh, Byung‐Hee

Mayo Clinic

Heart | February 16, 2019 | Volume: 105 | Issue: 3 | Pages: 235-242

10.1136/heartjnl-2018-313351 | PMID 30209126 Get It

Objectives Compare the effect of apixaban and warfarin on coagulation and primary haemostasis biomarkers in atrial fibrillation (AF). Methods The biomarker substudy from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial included 4850 patients with AF randomised to treatment with apixaban or warfarin. Sixty per cent of patients used vitamin K antagonist (VKA) within 7 days before randomisation. Prothrombin fragment 1+2 (F1+2), D-dimer, soluble CD40 ligand (sCD40L) and von Willebrand factor (vWF) antigen were analysed at randomisation and after 2 months of study treatment. Results In patients not on VKA treatment at randomisation, F1+2 and D-dimer levels were decreased by 25% and 23%, respectively, with apixaban, and by 59% and 38%, respectively, with warfarin (p<0.0001 for treatment differences for both). In patients on VKA at randomisation, F1+2 and D-dimer levels increased by 41% and 10%, respectively, with apixaban and decreased by 37% and 11%, respectively, with warfarin (p<0.0001 for treatment differences for both). sCD40L levels were slightly increased at 2 months, regardless of VKA or randomised treatment. Apixaban and warfarin also both reduced vWF antigen regardless of VKA treatment. The efficacy (stroke) and safety (bleeding) of apixaban compared with warfarin was similar irrespectively of biomarker levels at 2 months. Conclusions Treatment with apixaban compared with warfarin for stroke prevention in patients with AF was associated with less reduction in thrombin generation and fibrin turnover. This effect of apixaban could contribute to the clinical results where apixaban was superior to warfarin both in stroke prevention and in reducing bleeding risk. Trial registration number NCT00412984.
Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity
Zhang, Yong‐Jie , Guo, Lin , Gonzales, Patrick , Gendron, Tania F. , Wu, Yanwei , Jansen‐West, Karen , O’Raw, Aliesha D. , Pickles, Sarah , Prudencio, Mercedes , Carlomagno, Yari , Gachechiladze, Mariam A. , Tian, Ruilin , Chew, Jeannie , DeTure, Michael , Lin, Wen-Lang, Tong, Jimei, Daughrity, Lillian M. , Yue, Mei, Song, Yuping , Andersen, Jonathan W. , Castanedes‐Casey, Monica , Kurti, Aishe, Antognetti, Giovanna, McCampbell, Alexander , Rademakers, Rosa , Oskarsson, Björn , Kampmann, Martin , Ward, Michael E. , Fryer, John Denis , Link, Christopher D. , Shorter, James , Petrucelli, Leonard , Gonzales, Patrick K , Pickles, Sarah R , Chew, Jeannie , DeTure, Michael , Daughrity, Lillian M , Castanedes-Casey, Monica , McCampbell, Alexander , Rademakers, Rosa , Oskarsson, Björn , Dickson, Dennis W , Kampmann, Martin , Ward, Michael E , Shorter, James , Petrucelli, Leonard , Zhang, Yong-Jie , Prudencio, Mercedes , O'Raw, Aliesha , Gendron, Tania F , Guo, Lin , Ludwig, Connor , Datta, Abhishek, Dickson, Dennis W.

Mayo Clinic

Science | February 15, 2019 | Volume: 363 | Issue: 6428 | Pages: No page available

10.1126/science.aav2606 | PMID 30765536 Get It

How dipeptide repeats cause pathology A repeat expansion in the chromosome 9 open reading frame 72 ( C9orf72 ) gene is the most common known cause of two neurodegenerative diseases: frontotemporal dementia and amyotrophic lateral sclerosis. This expansion leads to the abnormal production of proteins of repeating dipeptides, but their contribution to disease pathogenesis remains unclear. Zhang et al. engineered a mouse model to study the consequences of one of these dipeptides—prolinearginine dipeptide repeat protein, poly(PR)—in the brain. They found that poly(PR) caused neuron loss as well as motor and memory impairments. These detrimental effects resulted from poly(PR)-induced perturbation of heterochromatin function, a tightly packed form of DNA that represses gene expression. Science , this issue p. eaav2606
An unusual presentation of late-onset Alexander’s disease with slow orthostatic tremor and a novel GFAP variant
Stitt, Derek , Gavrilova, Ralitza H. , Watson, Robert E. , Hassan, Anhar , Stitt, Derek W, Watson, Robert

Mayo Clinic

Neurocase | February 13, 2019 | Volume: 24 | Issue: 5-6 | Pages: 266-268

10.1080/13554794.2019.1580749 | PMID 30755139 Get It

Temporary balloon occlusion of atrial septal defects in suspected or documented left ventricular diastolic dysfunction: Hemodynamic and clinical findings
Miranda, William R. , Hagler, Donald J. , Reeder, Guy S., Warnes, Carole A. , Connolly, Heidi M. , Egbe, Alexander C. , Taggart, Nathaniel W. , Taggart, Nathaniel W

Mayo Clinic

Catheterization and Cardiovascular Interventions | February 12, 2019 | Volume: 93 | Issue: 6 | Pages: 1069-1075

10.1002/ccd.28150 | PMID 30747481 Get It

AbstractObjectiveTo review our experience with balloon testing prior to atrial septal defect (ASD) closure in adults with left ventricular (LV) diastolic dysfunction.BackgroundASD closure in patients with LV diastolic dysfunction may precipitate LV failure. Temporary ASD occlusion has been used in this scenario but data are limited.MethodsRetrospective review of 27 patients age ≥ 50 years undergoing temporary ASD balloon occlusion between 2000 and 2018 for suspected LV diastolic dysfunction or elevated LV end‐diastolic pressure (LVEDP).ResultsMedian age was 72 years (IQR 66.7; 75.2). Atrial fibrillation was seen in 58% of patients, hypertension in 58%, and coronary artery disease in 26%; 52% were females. Median ASD size was 13 mm (10; 18) and Qp/Qs 1.8 (1.6; 2.2). Median LVEDP was 14 mmHg (12; 22); pulmonary artery wedge pressure (PAWP) 12 mmHg (9; 16.5) and left atrial pressure (LAP) 13.5 mmHg (8; 16.3). After a median of 5 min (3; 10) of balloon occlusion, patients with baseline LVEDP ≥15 mmHg had more significant increases in LVEDP (9 [6; 12] vs. 2 mmHg [0.5; 5]; p = 0.03) and LAP/PAWP (10.5 [8.3; 16.3] vs. 1.5 mmHg [−1.5; 3]; p = 0.0003) than those with baseline LVEDP <15 mmHg. None of those with a baseline LVEDP <15 mmHg had a LAP/PAWP >15 mmHg during balloon testing compared to 92% of patients with a baseline LVEDP ≥15 mmHg.ConclusionLVEDP might be used to predict LAP post‐ASD closure. Comorbidities typically associated with LV diastolic dysfunction are common in these patients and should be considered in their management.
3D Printing for Bio-Synthetic Biliary Stents
Boyer, Christen J., Boktor, Moheb , Samant, Hrishikesh , White, Luke A. , Wang, Yuping , Ballard, David H. , Huebert, Robert C. , Woerner, Jennifer E., Ghali, Ghali E., Alexander, J. Steven , Alexander, J Steven , Huebert, Robert , Ballard, David H

Mayo Clinic

Bioengineering | February 12, 2019 | Volume: 6 | Issue: 1 | Pages: 16

10.3390/bioengineering6010016 | PMID 30744131 Get It

Three-dimensional (3D) printing is an additive manufacturing method that holds great potential in a variety of future patient-specific medical technologies. This project validated a novel crosslinked polyvinyl alcohol (XL-PVA) 3D printed stent infused with collagen, human placental mesenchymal stem cells (PMSCs), and cholangiocytes. The biofabrication method in the present study examined 3D printing and collagen injection molding for rapid prototyping of customized living biliary stents with clinical applications in the setting of malignant and benign bile duct obstructions. XL-PVA stents showed hydrophilic swelling and addition of radiocontrast to the stent matrix improved radiographic opacity. Collagen loaded with PMSCs contracted tightly around hydrophilic stents and dense choloangiocyte coatings were verified through histology and fluorescence microscopy. It is anticipated that design elements used in these stents may enable appropriate stent placement, provide protection of the stent-stem cell matrix against bile constituents, and potentially limit biofilm development. Overall, this approach may allow physicians to create personalized bio-integrating stents for use in biliary procedures and lays a foundation for new patient-specific stent fabrication techniques.
Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity
Marini, Sandro, Crawford, Katherine, Morotti, Andrea, Lee, Myung J., Pezzini, Alessandro, Moomaw, Charles J., Flaherty, Matthew L., Montaner, Joan, Roquer, Jaume, Jimenez-Conde, Jordi, Giralt-Steinhauer, Eva, Elosua, Roberto, Cuadrado-Godia, Elisa, Soriano-Tarraga, Carolina, Slowik, Agnieszka, Jagiella, Jeremiasz M., Pera, Joanna, Urbanik, Andrzej, Pichler, Alexander, Hansen, Björn M., McCauley, Jacob L., Tirschwell, David L., Selim, Magdy, Brown, Devin L., Silliman, Scott L., Worrall, Bradford B., Meschia, James F., Kidwell, Chelsea S., Testai, Fernando D., Kittner, Steven J., Schmidt, Helena, Enzinger, Christian, Deary, Ian J., Rannikmae, Kristiina, Samarasekera, Neshika, Salman, Rustam Al-Shahi, Sudlow, Catherine L., Klijn, Catharina J. M., Nieuwenhuizen, Koen M. van, Fernandez-Cadenas, Israel, Delgado, Pilar, Norrving, Bo, Lindgren, Arne, Goldstein, Joshua N., Viswanathan, Anand, Greenberg, Steven M., Falcone, Guido J., Biffi, Alessandro, Langefeld, Carl D., Woo, Daniel, Rosand, Jonathan, Anderson, Christopher D., Hardy, John , Benjamin, Emelia J. , Montaner, Joan , Rotter, Jerome I. , Seshadri, Sudha , Anderson, Christopher D. , Lubitz, Steven A. , Sudlow, Cathie , Rannikmäe, Kristiina , James, Michael L. , Testai, Fernando D. , Maguire, Jane , Brown, Devin L. , Tirschwell, David , Hansen, Björn M. , Elosúa, Roberto , Cuadrado‐Godia, Elisa , Soriano‐Tárraga, Carolina , Nieuwenhuizen, Koen M. van , Klijn, Catharina J.M. , Samarasekera, Neshika , Salman, Rustam Al‐Shahi , Pezzini, Alessandro , Delgado, Pilar , Lee, Chaeyoung , McCauley, Jacob L. , Marini, Sandro , Chen, Christopher , Bersano, Anna , van Nieuwenhuizen, Koen M , Seshadri, Sudha , Hardy, John , Montaner, Joan , Benjamin, Emelia J , Lubitz, Steven A , Rotter, Jerome I , Pezzini, Alessandro , Crawford, Katherine, Morotti, Andrea, Lee, Myung J., Moomaw, Charles J., Flaherty, Matthew L., Roquer, Jaume, Jimenez-Conde, Jordi, Giralt-Steinhauer, Eva, Slowik, Agnieszka, Jagiella, Jeremiasz M., Pera, Joanna, Urbanik, Andrzej, Pichler, Alexander, Hansen, Björn M., Selim, Magdy, Brown, Devin L., Silliman, Scott L., Worrall, Bradford B., Meschia, James F., Kidwell, Chelsea S., Kittner, Steven J., Schmidt, Helena, Enzinger, Christian, Deary, Ian J., Salman, Rustam Al-Shahi, Fernandez-Cadenas, Israel, Delgado, Pilar, Norrving, Bo, Lindgren, Arne, Goldstein, Joshua N., Viswanathan, Anand, Greenberg, Steven M., Falcone, Guido J., Biffi, Alessandro, Langefeld, Carl D., Woo, Daniel, Rosand, Jonathan, Anderson, Christopher D., Al-Shahi Salman, Rustam , Bersano, Anna , Testai, Fernando D , McCauley, Jacob L

Mayo Clinic

JAMA Neurology | February 6, 2019 | Volume: 76 | Issue: 4 | Pages: 480

10.1001/jamaneurol.2018.4519 | PMID 30726504 Get It

Practice, But Verify: A Novel Method to Assess Compliance With Lung Protective Ventilation Using Electronic Health Record Data*
Barwise, Amelia , Niven, Alexander S. , Barwise, Amelia K , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | January 30, 2019 | Volume: 47 | Issue: 1 | Pages: 131-133

10.1097/ccm.0000000000003490 | PMID 30557246 Get It

Abstract TP585: Long-Term Outcomes in Unruptured Brain Arteriovenous Malformation Patients: The Multicenter Arteriovenous Malformation Research Study (MARS)
Lawton, Michael T. , Mohr, J.P. , Moy, Claudia S., Pereira, V Mendes, Ribeiro, Diego Sgarabotto , Zaroff, Jonathan G. , Zhao, Yuanli , Kim, Helen , Salman, Rustam Al‐Shahi , Flemming, Kelly D. , Flint, Alexander C. , Hess, Christopher Paul , Hetts, Steven W. , Krings, Timo , Laakso, Aki , Lanzino, Giuseppe , McCulloch, Charles E. , Morgan, Michael K. , Nakaji, Peter , Stapf, Christian , Stefani, Marco Antônio

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.tp585 Get It

Introduction: Accurately balancing risks of interventional treatment and intracranial hemorrhage (ICH) in the untreated course of unruptured brain arteriovenous malformation (uBAVM) patients is critical for optimal management. Observational studies of uBAVM afford an opportunity to address important gaps and previous criticisms of randomized data to help guide treatment decisions and assess long-term risk/benefit ratio. We previously published an individual patient data meta-analysis (IPDMA) in 4 MARS cohorts and identified ICH presentation and increasing age as significant predictors of ICH during follow-up, but was not powered to detect predictors in those with uBAVM. Thus, the goals of this project are to identify risk factors for ICH in uBAVMs, to estimate the risk with precision, and to create personalized, risk-prediction models. Methods: MARS is an international, multi-center study of 11 cohorts with target enrollment of 4,500 uBAVM patients ascertained through population-based or referral-based studies. We are harmonizing both retrospective and prospective data, including clinical, lifestyle, imaging, and angiographic factors. Treatments, complications, and functional outcomes (physician and patient-reported) will be updated annually between 2018-2022. We propose to: 1) identify predictors of outcome in uBAVMs using IPDMA; 2) test whether long-term outcomes differ by treatment using statistical approaches for causal inference and unbiased estimates; 3) compare treatment outcomes in randomized and non-randomized data to address generalizability; and 4) validate models and provide a novel tool for calculating individualized risks. Eligible sites have: a) prior BAVM publications; b) data from a minimum of 100 uBAVM patients; c) agree to random outcome adjudication; and d) agree to MARS data sharing policy. Discussion: The NIH-funded MARS consortium will provide important and comprehensive characterization of the untreated and treated course of uBAVMs, using large observational datasets and sophisticated epidemiological approaches. The data and models generated will be a useful resource for decision-making. We welcome participation from eligible sites with longitudinal data on uBAVM patients
Abstract 17: Apolipoprotein E and Intracerebral Hemorrhage: A Trans-Ethnic Meta-Analysis
Morotti, Andrea , Moomaw, Charles J. , Flaherty, Matthew L. , Jiménez-Conde, Jordi , Słowik, Agnieszka , Pichler, Alexander , Tirschwell, David L, Brown, Devin L. , Silliman, Scott, Worrall, Bradford B. , Kidwell, Chelsea S., Kittner, Steven J. , Sudlow, Catherine L, Viswanathan, Anand , Greenberg, Steven M. , Falcone, Guido J. , Langefeld, Carl D. , Woo, Daniel , Marini, Sandro , Pezzini, Alessandro , Montaner, Joan , Cuadrado‐Godia, Elisa , Tirschwell, David L, Selim, Magdy H. , Meschia, James F. , Testai, Fernando D. , Deary, Ian J. , Salman, Rustam Al‐Shahi , Sudlow, Catherine L, Klijn, Catharina J.M. , Fernández‐Cadenas, Israel , Lindgren, Arne G. , Goldstein, Joshua Norkin , Rosand, Jonathan M. , Anderson, Christopher D.

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.17 Get It

Introduction: Risk of lobar and non-lobar intracerebral hemorrhage (ICH) varies among blacks, whites and Hispanics. We sought to determine whether these differences could be due to variability in the effects of Apolipoprotein E (APOE) epsilon (ε) alleles, the most potent genetic risk factor for ICH. Methods: Primary ICH cases and controls were collected from US and European sites contributing to the International Stroke Genetic Consortium (ISGC). We meta-analyzed the effects of APOE allele status on ICH risk applying a two-stage clustering approach based on race/ethnicity and the contributing study. Models were adjusted for age, sex, history of hypertension, hypercholesterolemia, warfarin, statin and antiplatelet use, smoking and alcohol use. A propensity score analysis was used to model the influence of APOE against the burden of hypertension across races/ethnicities. Results: 13,124 subjects (54.5% male, median age 66 years) were included. In whites, APOE ε2 (odds ratio (OR)=1.85, 95% confidence interval (CI)=1.27-2.69, p<0.001) and APOE ε4 (OR=1.94, 95% CI=1.58-2.38, p<0.001) were independently associated with lobar ICH risk, however within self-identified Hispanics and blacks, no associations were found (Figure). After propensity score-matching for hypertension burden, APOE ε4 was associated with lobar ICH risk among whites (OR=1.12, 95% CI=1.08-1.17) and Hispanics (OR=1.07, 95% CI=1.01-1.15, p=0.01), but not blacks (OR=1.02 95% CI=0.98-1.07, p=0.251). APOE ε2 and ε4 did not show an effect on non-lobar ICH risk in any race/ethnicity. Conclusion: APOE ε4 and ε2 alleles affect lobar ICH risk variably by race and ethnicity. Associations are confirmed in whites but can be shown in Hispanics only when the excess burden of hypertension is propensity score-matched. Further studies are needed to explore interactions between APOE alleles and environmental exposures that vary by race and ethnicity in representative populations at risk for ICH.